Special Drug Use Investigation for PAXIL Tablet (Pediatric Panic Disorder)

• Status: Completed
• Trial end date: 2009-05-01
• Target enrollment: 0
• Participant gender: All

Summary

The objectives of this survey was to retrospectively collect and evaluate the information on the efficacy and safety of PAXIL tablets ("PAXIL", hereinafter) in pediatric subjects (aged under 18) with panic disorder under conditions of actual use.

Details

• Lead Sponsor: GlaxoSmithKline
• Treatments: Paroxetine

Criteria

Inclusion Criteria:

• Aged under 18 at the time of the panic disorder diagnosis

• Aged under 18 on the starting day of PAXIL treatment

• Having been making periodic visits to the hospital to receive treatment for panic disorder

Exclusion Criteria:

• Subjects who have been treated with paroxetine prior to this investigation

• Subjects with hypersensitivity to paroxetine

• Subjects taking monoamine oxidase inhibitors (MAOIs) or within 2 weeks of stopping treatment with MAOIs

• Concomitant use in patients taking pimozide